Author

Delphine Martineau

Institution: Centre Hospitalier de la Côte Basque

Observed institutions: Université de Bordeaux, Inserm, Centre Hospitalier Universitaire de Bordeaux, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier de la Côte Basque, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers

ORCID: 0000-0003-0502-9059

Observed ORCID: 0000-0003-0502-9059

OpenAlex ID: A5084881688

Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3 -ITD Acute Myeloid Leukemia

2021 · Pierre-Yves Dumas, Arnaud Villacreces, et al. · Clinical Cancer Research · 40

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

2021 · Florent Malard, Michael Loschi, et al. · Blood · 8

Delay in Diagnosis of Influenza Virus in an Elderly Hospitalized Patient: A Fatal Outcome

2012 · Nicole Haber, Djamal Khelili, et al. · Clinical Medicine Insights Case Reports · 8

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

2020 · Florent Malard, Michael Loschi, et al. · Blood · 7

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

2026 · Gaetan Basile, Arnaud Neuville, et al. · Haematologica · 2

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

2023 · Eric Deconinck, Berengere Gruson, et al. · Blood · 1

Supplementary Data from Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia

2023 · Pierre-Yves Dumas, Arnaud Villacreces, et al.

Data from Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia

2023 · Pierre-Yves Dumas, Arnaud Villacreces, et al.

Étude rétrospective et multicentrique de l’association du Brentuximab Vedotin et de la Bendamustine dans le lymphome de Hodgkin réfractaire ou en rechute et revue de la littérature

2018 · Delphine Martineau · HAL

Works count: 9

Citation count: 66

H-index: 4

I10-index: 1